Peptides for type 1 diabetes: what the evidence shows

Do peptides help with type 1 diabetes?

3 peptides are graded for type 1 diabetes on this page. The strongest grade is human RCT evidence, for insulin, pramlintide, and glucagon. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for type 1 diabetes?

Multiple daily insulin injections or an insulin pump, ideally with continuous glucose monitoring; carbohydrate counting and structured education; a glucagon rescue product for everyone on insulin; regular screening for eye, kidney, nerve, and cardiovascular complications. Teplizumab can delay clinical onset in people with stage 2 disease.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for type 1 diabetes?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Type 1 diabetes with evidence grades
Peptide	Evidence for this use	Note
Insulin	Evidence: Human RCT evidence	DCCT (n = 1,441) showed intensive insulin therapy reduced the onset and progression of retinopathy, nephropathy, and neuropathy versus conventional therapy. [1] [6]
Pramlintide	Evidence: Human RCT evidence	Lowered HbA1c by about 0.4 versus 0.1 percentage points on placebo, with about 1 kg less weight, as an insulin adjunct; carries a boxed warning for severe hypoglycemia. [2] [5]
Glucagon	Evidence: Human RCT evidence	Nasal glucagon 3 mg matched intramuscular glucagon for insulin induced hypoglycemia (98.7% versus 100% success), and dasiglucagon restored glucose in a median 10 minutes versus 40 on placebo. [3] [4] [7]

Frequently asked questions

Which peptide has the strongest evidence for type 1 diabetes?

Insulin, pramlintide, and glucagon have the strongest evidence among the peptides graded here, at human RCT evidence. Insulin: DCCT (n = 1,441) showed intensive insulin therapy reduced the onset and progression of retinopathy, nephropathy, and neuropathy versus conventional therapy. Pramlintide: Lowered HbA1c by about 0.4 versus 0.1 percentage points on placebo, with about 1 kg less weight, as an insulin adjunct; carries a boxed warning for severe hypoglycemia. Glucagon: Nasal glucagon 3 mg matched intramuscular glucagon for insulin induced hypoglycemia (98.7% versus 100% success), and dasiglucagon restored glucose in a median 10 minutes versus 40 on placebo. [1] [2] [5] [6]

Is any peptide FDA approved for type 1 diabetes?

Insulin, pramlintide, and glucagon are FDA approved drugs, but an approval covers only the indications on that label, so check the label before assuming it applies to type 1 diabetes. [1] [2] [5] [6] [8]

Has any peptide been tested in a randomized trial for type 1 diabetes?

Yes, for insulin, pramlintide, and glucagon. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2] [5] [6]